171 related articles for article (PubMed ID: 33026204)
1. [Long-term efficacy and safety of etelcalcetide in hemodialysis patients with severe secondary hyperparathyroidism].
Massimetti C; Tondo M; Feriozzi S
G Ital Nefrol; 2020 Oct; 37(5):. PubMed ID: 33026204
[No Abstract] [Full Text] [Related]
2. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
3. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
4. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
[TBL] [Abstract][Full Text] [Related]
5. Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.
Morosetti M; Jankovic L; Zappalà L; Agafonova E; Pryshlyak I
Int Urol Nephrol; 2023 Jul; 55(7):1865-1873. PubMed ID: 36790677
[TBL] [Abstract][Full Text] [Related]
6. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
[TBL] [Abstract][Full Text] [Related]
7. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
Stephens JM; Fox KM; Desai P; Cheng S; Goodman WG; Kendrick JB
Hemodial Int; 2022 Apr; 26(2):243-254. PubMed ID: 34931443
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
[TBL] [Abstract][Full Text] [Related]
9. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
Nakamura H; Tokumoto M; Anayama M; Kurihara S; Makino Y; Tamura K; Nagasawa M
CEN Case Rep; 2022 May; 11(2):254-258. PubMed ID: 34787825
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
[TBL] [Abstract][Full Text] [Related]
11. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
Dudar I; Shifris I; Dudar S; Kulish V
Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
[TBL] [Abstract][Full Text] [Related]
12. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
13. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
[TBL] [Abstract][Full Text] [Related]
14. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
15. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
[TBL] [Abstract][Full Text] [Related]
16. [Cholecalciferol supplementation improves secondary hyperparathyroidism control in hemodialysis patients].
Massimetti C; Bellasi A; Feriozzi S
G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530156
[No Abstract] [Full Text] [Related]
17. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
18. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
Friedl C; Zitt E
Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness.
Karaboyas A; Muenz D; Hwang Y; Goodman W; Cheng S; Desai P; Fox KM; Robinson BM; Pisoni RL
Kidney Med; 2022 Jun; 4(6):100475. PubMed ID: 35637925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
